Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
Now Approved!
Who We Are
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
Our Technology
EyePoint has developed five products approved by the FDA for, sustained-release delivery of drugs to the eye.
Our Pipeline
EyePoint has a number of products in development that utilize our proven DurasertTM and Verisome Technology platforms®.
About EyePoint
Latest EyePoint News
- EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan
- EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
- EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
- EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress